Retatrutide (LY3437943) has emerged as one of the most closely watched compounds in metabolic peptide research. As a triple receptor agonist with activity at GLP-1, GIP, and glucagon receptors simultaneously, it represents a distinct approach compared to single and dual agonist compounds that have preceded it.
Access verified quality documentation and research-grade peptides.
View Certificates of Analysis Explore Research-Grade PeptidesDisclaimer: All compounds referenced in this article are intended for laboratory research use only. They are not approved for human or veterinary use by the FDA or any regulatory agency.